“Profound knowledge, excellent support and good customer service skills.”
“Strong on IP-related litigation and arbitration on both domestic and cross-border issues.”
“Well known for work in the life sciences space” / “Advice has always been timely and of the highest quality.”
“A courtroom favourite among major life sciences players.”
Schellenberg Wittmer’s Life Sciences Group is a leading practice for dispute resolution, transactional work and regulatory matters in the field of life sciences. We advise and represent companies from a variety of sectors, including pharma, biotechnology, medical devices, cosmetics, and food and beverages.
Schellenberg Wittmer’s Life Sciences Group has broad expertise in representing life sciences clients in complex international disputes and in advising on corporate and commercial matters, such as complex licensing deals, joint ventures and M&A transactions. Additionally, we provide guidance in regulatory matters and advise on data protection, compliance and investigations, e-health, software and competition law.
Litigation/Arbitration
We represent clients in litigation, arbitration and mediation proceedings over a broad range of issues, including:
Corporate and Commercial
Advice and Regulatory
31.07.2023
Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici S.p.A. The transaction replaces the existing license …
20.07.2023
Schellenberg Wittmer acted as co-counsel for Sosei Heptares on its acquisition of Idorsia Pharmaceuticals Ltd's pharmaceuticals business in Japan and APAC.
13.07.2023
Schellenberg Wittmer has been awarded "Switzerland Firm of the Year" at the prestigious LMG Life Sciences Awards EMEA 2023.
The group and leading practitioners are well recognised among leading law firms across international directories and publications:
